Many Patients With Hard-to-Treat Hypertension Don’t Take Their Meds

Nearly 20% of people with hard-to-treat high blood pressure are not taking all of their medication as directed. Even more troubling, an additional 20% don’t take any of the drugs they are prescribed.

Resistant hypertension is defined as having high blood pressure despite taking 3 or more medications to control it. But new research out of the Netherlands indicates that many of these people – who often seek a medical specialist – may go through unnecessary tests since the lack of medication adherence can result in resistant hypertension.

In the study, researchers randomly assigned 95 patients to undergo renal denervation – a treatment used in resistant hypertension – while not changing the meds they were taking. Renal denervation uses a catheter inserted into a blood vessel in the groin and fed until it enters the artery feeding the kidney. Radio waves or ultrasound destroy sections of the nerves sending messages between the brain and the kidneys. A control group of 44 patients just remained on their drugs.

Results showed that 31% of patients either improved or lessened their medication compliance. And in patients who had a similar amount of medication in their blood at each assessment, those receiving renal denervation saw their systolic blood pressure fall by a few points more than those in the control group.

“At a minimum, be open and honest and tell your physician if you don’t want to take your pills for any reason,” said Peter Blankestijn, MD, PhD, the study’s senior author and professor of nephrology and hypertension at the University Medical Center Utrecht. “You and your doctor can discuss options for changing the type of pill or the dose if needed. There are many effective blood pressure pills and the majority of patients with high blood pressure can be successfully treated.”


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

Breaking News – EpiPen Malfunction

Breaking News – EpiPen Malfunction

Just released from the FDA – Pfizer has informed the FDA that they are aware of several continuing problems that people are having using the EpiPen (epinephrine) and EpiPen Jr (epinephrine) auto-injectors and generic versions. Some of the problems are from user error and some from EpiPen malfunction. Here are…

ACE Inhibitors in the Time of Coronavirus

ACE Inhibitors in the Time of Coronavirus

Are you worried about ACE inhibitors and coronavirus? You may be hearing that one of the entry methods for the coronavirus in humans is by attaching to the ACE-2 enzyme. This has raised alarms among those with heart disease who use ACE inhibitors (with names ending in -pril, such as…

  • Advertisement